Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 14, 2014 (12 years ago)

Miconazole Nitrate active pharmaceutical ingredient packaged in…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Miconazole Nitrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada

Drug: Miconazole

Recalling firm
Attix Pharmaceuticals
Origin
Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-797-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Miconazole recalls

See all
Class II · Moderate risk

DermaFungal

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-234-05 D-0162-2026
Class II · Moderate risk

Medline Remedy Clinical TREAT Antifungal Cream

Labeling: Not Elsewhere Classified; Product labeling contains the claim of 'Paraben Free' while the product does in fact contain parabens as part of the formulation/ ingredient list.

Ongoing Labeling / mix-up MEDLINE INDUSTRIES, LP - Northfield D-0315-2024
Class II · Moderate risk

Clinical TREAT Antifungal Powder

CGMP deviations: the product was shipped from the Manufacturer to a Medline warehouse and released to stock while it was still under investigation for low assay results on the active ingredient miconazole nitrate.

Terminated Wrong potency / content MEDLINE INDUSTRIES, LP - Northfield D-0091-2024

Other recalls by Attix Pharmaceuticals

All 2014 recalls
Class III · Low risk

Mycophenolate Mofetil

cGMP deviation; manufacturer is Not Registered with the Food and Drug Administration

Terminated cGMP deviation Attix Pharmaceuticals Inc D-1047-2016
Class II · Moderate risk

Zonisamide active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-960-2015
Class II · Moderate risk

Zolmitriptan active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-959-2015
Class II · Moderate risk

Zoledronic Acid active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-958-2015